Reference : Pharmacokinetic considerations for the treatment of diabetes in patients with chronic...
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
Human health sciences : Endocrinology, metabolism & nutrition
http://hdl.handle.net/2268/145993
Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.
English
SCHEEN, André mailto [Centre Hospitalier Universitaire de Liège - CHU > > Diabétologie,nutrition, maladies métaboliques >]
2013
Expert Opinion on Drug Metabolism and Toxicology
Yes (verified by ORBi)
International
1742-5255
[en] Renal impairment ; Type 2 diabetes mellitus ; Glomerular filtration rate ; Glucose-lowering therapy ; Pharmacokinetics ; Chronic kidney disease ; Oral antidiabetic agent
[en] Introduction: People with chronic kidney disease (CKD) of stages 3 - 5 (creatinine clearance < 60 ml/min) represent approximately 25% of patients with type 2 diabetes mellitus (T2DM), but the problem is underrecognized or neglected in clinical practice. However, most oral antidiabetic agents have limitations in case of renal impairment (RI), either because they require a dose adjustment or because they are contraindicated for safety reasons. Areas covered: The author performed an extensive literature search to analyze the influence of RI on the pharmacokinetics (PK) of glucose-lowering agents and the potential consequences for clinical practice. Expert opinion: As a result of PK interferences and for safety reasons, the daily dose should be reduced according to glomerular filtration rate (GFR) or even the drug is contraindicated in presence of severe CKD. This is the case for metformin (risk of lactic acidosis) and for many sulfonylureas (risk of hypoglycemia). At present, however, the exact GFR cutoff for metformin use is controversial. New antidiabetic agents are better tolerated in case of CKD, although clinical experience remains quite limited for most of them. The dose of DPP-4 inhibitors should be reduced (except for linagliptin), whereas both the efficacy and safety of SGLT2 inhibitors are questionable in presence of CKD.
http://hdl.handle.net/2268/145993
10.1517/17425255.2013.777428

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
TXT-Revised Clean PK Diabetes CKD EODMT Feb 2013.pdfAuthor preprint302.09 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.